A Taiwanese Nationwide Cohort Study Shows Interferon-Based Therapy for Chronic Hepatitis C Reduces the Risk of Chronic Kidney Disease
| Autor: | Chia-Pin Wu, Chung Yi Li, Yi-Chun Chen, Li-Chu Lin, Shang-Jyh Hwang |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Taiwan Observational Study Comorbidity Antiviral Agents Cohort Studies Risk Factors Internal medicine Ribavirin Medicine Humans Cumulative incidence Risk factor Renal Insufficiency Chronic business.industry Incidence Hazard ratio Interferon-alpha General Medicine Hepatitis C Hepatitis C Chronic Middle Aged medicine.disease Cohort Physical therapy Number needed to treat ComputingMethodologies_DOCUMENTANDTEXTPROCESSING Female business Cohort study Kidney disease Research Article |
| Zdroj: | Medicine |
| ISSN: | 1536-5964 |
| Popis: | Supplemental Digital Content is available in the text Hepatitis C virus (HCV) infection is a risk factor for chronic kidney disease (CKD). However, it remains unclear whether interferon-based therapy (IBT) for HCV was associated with reduced risk of CKD. From the Taiwan National Health Insurance Research Database, we identified 919 patients who received 3 months or more of IBT as our treated cohort. This cohort was propensity score-matched 1:4 with 3676 controls who had never received IBT for HCV infection (untreated cohort). Cumulative incidences of and hazard ratios (HRs) for CKD were calculated after adjusting for competing mortality. In the matched HCV cohort, the risk of CKD was significantly lower in the treated cohort (7-year cumulative incidence, 2.6%; 95% confidence interval [CI], 0.7%–6.9%) than in the untreated cohort (4%; 95% CI, 3.5%–5.2%) (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|